Graybug Vision, Inc. (GRAY)
After hours:
| Previous Close | 0.9600 |
| Open | 0.9600 |
| Bid | 0.0000 x 2900 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.9212 - 0.9900 |
| 52 Week Range | 0.7200 - 3.7700 |
| Volume | |
| Avg. Volume | 393,574 |
| Market Cap | 20.033M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6220 |
| Earnings Date | Nov 09, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.17 |
- GlobeNewswire
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors w
- GlobeNewswire
Graybug to Present at the 2022 OIS Retina Innovation Summit
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming Ophthalmology Innovation Source (OIS) Retina Innovation Summit, to be held in New York City on July 13, 2022. Information about the event is listed below and available on the OIS Retina website. Graybug Pipeline Opportunities in Retin
- Zacks
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.
